Myeloma cell line–derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma

摘要: Tumor cell–derived heat shock proteins are used as vaccines for immunotherapy of cancer patients. However, current approaches require the generation custom-made products and clinically ineffective. To improve applicability protein–based in cancers to enhance clinical efficacy, we explored combinational treatments a myeloma setting using pooled heterogeneous or allogeneic cell line–derived glycoprotein 96 (gp96) universal vaccines, clearly demonstrated that but not single gp96 from lines was effective autologous protecting mice tumor challenge rechallenge treating established myeloma. We showed interferon γ CD4+ CD8+ T cells were required gp96-induced antimyeloma responses induced broader immune protected developing different Furthermore, plus CpG combination with anti-B7H1 anti–interleukin-10 monoclonal antibodies large burdens. Thus, this study strongly suggests can replace tumors induce against antigens may protect recurrence development unrelated vaccinated